June 7, 2022

Staff Writer: Deileta Kamhunga It’s well established that there are serious inequities in cancer care and outcomes in the U.S. and around the globe. But are pivotal clinical trials including populations representative of all patients, particularly those who experience these inequities? Researchers set out to determine if clinical trials for lymphomas reflect the populations affected...

Staff Writer: Deileta Kamhunga The survival rates of B-cell acute lymphoblastic leukemia (B-ALL) have been dramatically improved through relatively new therapies. One such therapy is CD19-directed chimeric antigen receptor T-cell (CART) therapy, which has improved survival rates, particularly in children with relapsed or refractory B-ALL. However, other external factors may also have a significant impact...

Although multiple myeloma cannot be cured, treatments are available to help improve symptoms and manage quality of life. However, while treatments can help control the disease, mortality remains a concern for patients with multiple myeloma and their healthcare providers. Little research has been conducted on end-of-life care for multiple myeloma patients. This retrospective population-based cohort...

African Americans tend to have a higher risk of developing multiple myeloma at an earlier age and a higher risk of death than whites. While certain factors, such as socioeconomic status and access to care, can affect the outcomes of multiple myeloma, there’s no question that genetic mutations may also play a significant role in...

Given the troubled history of Black Americans in previous clinical studies, such as the Tuskegee syphilis study, it is not surprising that Black Americans may feel a sense of lingering mistrust in clinical trials and medical research. Despite the increased risk and aggressive nature of prostate cancer in Black patients compared to white patients, a...

The development and outcomes of prostate cancer can be significantly affected by multiple factors, such as genetic, socioeconomic, and environmental factors. Given this multifactorial approach to prostate cancer, disaggregating the available data on racial and ethnic subgroups is vital to pinpoint disparities in treatment status and diagnosis. In particular, Hispanic subpopulations with metastatic prostate cancer...